

Oncology Oral Medications Solid Tumors Enrollment Form



Fax Referral To: 1-877-232-5455

Address: 500 Ala Moana Blvd., Ste 1-A Honolulu, HI 96813

Phone: 1-800-896-1464

Six Simple Steps to Submitting a Referral

1 PATIENT INFORMATION (Complete or include demographic sheet)

Patient Name: _____ DOB: _____
 Address: _____ City, State, ZIP Code: _____
 Gender: Male Female
 Preferred Contact Methods: Phone (to primary # provided below) Text (to cell # provided below) Email (to email provided below)
Note: Carrier charges may apply. If unable to contact via text or email, Specialty Pharmacy will attempt to contact by phone.
 Primary Phone: _____ Alternate Phone: _____
 If **Minor**, Parent/Caregiver/Guardian Name (Last, First): _____
Relationship to minor: _____
 Email: _____ Last Four of SSN: _____ Primary Language: _____

2 PRESCRIBER INFORMATION

Prescriber's Name: _____ State License #: _____
 NPI #: _____ DEA #: _____ Group or Hospital: _____
 Address: _____ City, State, ZIP Code: _____
 Phone: _____ Fax: _____ Contact Person: _____ Contact's Phone: _____

3 INSURANCE INFORMATION Please fax copy of prescription and insurance cards with this form, if available (front and back)

4 DIAGNOSIS AND CLINICAL INFORMATION

Needs by Date: _____ Ship to: Patient Office Other: _____
Diagnosis (ICD-10):
 Code: _____ Description: _____ Code: _____ Description: _____
 Code: _____ Description: _____ Code: _____ Description: _____

Patient Clinical Information:

Allergies: _____ Weight: _____ lb/kg Height: _____ in/cm BSA: _____ m²

5 PRESCRIPTION INFORMATION

Medications:

- | | | | |
|--|---|--|--|
| <input type="checkbox"/> Afinitor (everolimus) | <input type="checkbox"/> Iressa (gefitinib) | <input type="checkbox"/> Rubraca (rucaparib) | <input type="checkbox"/> Verzenio (abemaciclib) |
| <input type="checkbox"/> Afinitor Disperz (everolimus) | <input type="checkbox"/> Kisqali (ribociclib) | <input type="checkbox"/> Rozlytrek (entrectinib) | <input type="checkbox"/> Vitakvi (larotrectinib) |
| <input type="checkbox"/> Alecensa (alectinib) | <input type="checkbox"/> Lenvima (lenvatinib) | <input type="checkbox"/> Stivarga (regorafenib) | <input type="checkbox"/> Vizimpro (dacomitinib) |
| <input type="checkbox"/> Braftovi (encorafenib) | <input type="checkbox"/> Lonsurf (trifluridine & tipiracil) | <input type="checkbox"/> Sutent (sunitinib malate) | <input type="checkbox"/> Votrient (pazopanib) |
| <input type="checkbox"/> Cabometyx (cabozantinib) | <input type="checkbox"/> Lorbrena (lorlatinib) | <input type="checkbox"/> Taltrex (capmatinib) | <input type="checkbox"/> Xalkori (crizotinib) |
| <input type="checkbox"/> Cometriq (cabozantinib) | <input type="checkbox"/> Lumakras (sotorasib) | <input type="checkbox"/> Tafinlar (dabrafenib) | <input type="checkbox"/> Xeloda (capecitabine) |
| <input type="checkbox"/> Cotellic (cobimetinib) | <input type="checkbox"/> Lynparza (olaparib) | <input type="checkbox"/> Tagrisso (osimertinib) | <input type="checkbox"/> Xtandi (enzalutamide) |
| <input type="checkbox"/> Cytosan Capsules (cyclophosphamide) | <input type="checkbox"/> Mekinist (trametinib) | <input type="checkbox"/> Talzena (talazoparib) | <input type="checkbox"/> Yonsa (abiraterone acetate) |
| <input type="checkbox"/> Erivedge (vismodegib) | <input type="checkbox"/> Mektovi (binimetinib) | <input type="checkbox"/> Tarceva (erlotinib) | <input type="checkbox"/> Zejula (niraparib) |
| <input type="checkbox"/> Erleada (apalutamide) | <input type="checkbox"/> Nerlynx (neratinib) | <input type="checkbox"/> Targretin Capsules (bexarotene) | <input type="checkbox"/> Zelboraf (vemurafenib) |
| <input type="checkbox"/> Gavreto (pralsetinib) | <input type="checkbox"/> Nexavar (sorafenib) | <input type="checkbox"/> Temodar Capsules (temozolomide) | <input type="checkbox"/> Zolinda (vorinostat) |
| <input type="checkbox"/> Hycamtin Capsules (topotecan) | <input type="checkbox"/> Nubeqa (darolutamide) | <input type="checkbox"/> Tykerb (lapatinib) | <input type="checkbox"/> Zykadia (ceritinib) |
| <input type="checkbox"/> Ibrance (palbociclib) | <input type="checkbox"/> Odomzo (sonidegib) | <input type="checkbox"/> Vepesid Capsules (etoposide) | <input type="checkbox"/> Zytiga (abiraterone) |
| <input type="checkbox"/> Inlyta (axitinib) | <input type="checkbox"/> Piqray (alpelisib) | | <input type="checkbox"/> Other _____ |
| | <input type="checkbox"/> Retevmo (selpercatinib) | | |

PRESCRIPTIONS	DRUG NAME/STRENGTH	SIG/DIRECTIONS	QUANTITY/REFILLS
RX 1	<input type="checkbox"/> Other: _____	<input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
RX 2	<input type="checkbox"/> Other: _____	<input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____
RX 3	<input type="checkbox"/> Anastrozole <input type="checkbox"/> Letrozole <input type="checkbox"/> Exemestane <input type="checkbox"/> Prednisone <input type="checkbox"/> Fulvestrant <input type="checkbox"/> Zoladex	<input type="checkbox"/> Other: _____	Quantity: _____ Refills: _____

Patient is interested in patient support programs

STAMP SIGNATURE NOT ALLOWED

Ancillary supplies and kits provided as needed for administration

6 PRESCRIBER SIGNATURE REQUIRED (STAMP SIGNATURE NOT ALLOWED)

"Dispense As Written" / Brand Medically Necessary / Do Not Substitute / No Substitution / DAW / May Not Substitute Prescriber's Signature: _____ Date: _____	May Substitute / Product Selection Permitted / Substitution Permissible Prescriber's Signature: _____ Date: _____
CA, MA, NC & PR: Interchange is mandated unless Prescriber writes the words "No Substitution" _____ ATTN: New York and Iowa providers, please submit electronic prescription	

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature. **CONFIDENTIALITY NOTICE:** This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments. Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Pharmacy, Inc. or one of its affiliates. ©2022 CVS Pharmacy, Inc. or one of its affiliates. 75-35450A 05/17/22